|
Recent Developments |
|
12-MAR-15
Dr Datson Labs has forged a potential collaboration with Delhi based pharma company Ochoa Laboratories to produce oncology drugs to cater to the European market worth Rs 1.20 billion.
09-MAR-15
Indian drug maker Datsons Labs specializing in manufacturing of anti-malarial drugs has received the proposal to supply the artemesinin-based combination therapies (ACTs) to the Clinton Health Access Initiative (CHAI), the healthcare project ... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Dec-2014(9) | 31-Mar-2014 (12) | 31-Mar-2013(12) | | Net sales | 4865.85 | 4210.54 | 5207.57 | | Other Income | 92.85 | 78.71 | 47.08 | | Total Income | 4958.70 | 4289.25 | 5254.66 | | Cost of goods sold | 4657.39 | 3640.02 | 4149.66 | | OPBDIT | 301.31 | 649.23 | 1104.99 | | PAT | 1.00 | 6.74 | 5.49 | | Gross Block | - | - | - | | Equity capital | 1052.59 | 316.55 | 138.87 | | EPS (Rs.) | - | 0.19 | - | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | 155.79 - 660.79 | - | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 6.1 | 15.1 | 21.0 | | Net margin (% of OI) | 0.0 | 0.2 | 0.1 |
|
|
Detailed Financials
|
|
|
|
|
